Jubilant Pharmova Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Attractively valued vs sector (P/E 38.5x vs industry 50.2x)
Concerns
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,758 | ₹4.2L Cr | 33.2 | 5.05 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,559 | ₹2.4L Cr | 79.8 | 15.15 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,557 | ₹1.7L Cr | 79.3 | 9.43 | 27.4 | 15.2 | 0.77 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,176 | ₹1.1L Cr | 23.1 | 4.37 | 21.2 | 21.1 | 0.38 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,137 | ₹1.1L Cr | 52.8 | 12.35 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,366 | ₹1.1L Cr | 30.2 | 3.21 | 11.6 | 15.5 | 0.01 |
| LAURUSLABS Laurus Labs Limited | ₹2,182 | ₹1.1L Cr | 97.4 | 22.22 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
JUBLPHARMA · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 50.67% | 50.67% | 50.67% | 50.67% | 50.67% | 50.67% |
| FII | 20.29% | 19.06% | 19.50% | 17.94% | 16.96% | 17.23% |
| DII | 2.89% | 3.77% | 4.06% | 5.66% | 6.99% | 7.05% |
| Public | 25.56% | 25.91% | 25.18% | 25.17% | 24.82% | 24.48% |
| Others | 0.58% | 0.58% | 0.58% | 0.56% | 0.56% | 0.56% |
Corporate Events
To consider and approve raising of funds through the issuance of Non-Convertible Debentures (NCDs) and/or such other securities as may be permitted under applicable laws, and to approve seeking shareholders' approval, as may be required
JUBLPHARMA : 10-Aug-2026 : The Company has informed the Exchange that a Board meeting to be held on August 07, 2026 has been re-scheduled. Further, the Company has informed the Exchange that the meeting of the Board of Directors of the Company will be he
To consider and approve the financial results for the period ended Jun 30, 2026
Dividend - Rs 5 Per Share
Dividend - Rs 5 Per Share
Dividend - Rs 5 Per Share
Dividend - Rs 5 Per Share
Latest News
All newsJubilant Ingrevia announces change in management
*Jubilant Ingrevia announces change in management*. The company has filed a regulatory update regarding a shift in its management structure. While no financial details were disclosed, such changes can influence investor sentiment and operational direction. The impact hinges on the roles and profiles of incoming and outgoing executives. 📊 *STOCKS:* $JUBLINGVA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #ManagementChange
Jubilant Ingrevia announces board meeting outcomes.
*Jubilant Ingrevia announces board meeting outcomes.* The company disclosed outcomes from its October 27, 2026 board meeting. No major financials or strategic moves were detailed in the filing. Further updates expected in subsequent disclosures. 📊 *STOCKS:* $JUBLING | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #BoardMeeting
Jubilant Pharmova to issue NCDs via private placement
*Jubilant Pharmova to issue secured and unsecured redeemable non-convertible debentures.* The board approved private placement of **rated, listed NCDs** with October 12, 2026, as the reference date. The move aims to raise funds for general corporate purposes. No immediate equity dilution is expected. 📊 *STOCKS:* $JUBLPHARMA | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Funding
Jubilant Foodworks announces change in senior management
*Jubilant Foodworks announces change in senior management.* The company has filed a regulatory disclosure regarding a shift in its top leadership. Such changes may influence strategic direction and execution. Investors will watch for continuity in operations and guidance. 📊 *STOCKS:* $JUBLFOOD | 🏢 *SECTOR:* Corporate | #MEDIUMIMPACT #ManagementChange
Jubilant Foodworks announces change in senior management
*Jubilant Foodworks announces change in senior management.* The company has filed a regulatory disclosure regarding a shift in its top leadership. Such changes may influence investor sentiment and strategic direction. **No financial details or specific roles were disclosed.** 📊 *STOCKS:* $JUBLFOOD | 🏢 *SECTOR:* Food Services | #MEDIUMIMPACT #ManagementChange
Jubilant Foodworks reports Q1 FY27 financial results
*Jubilant Foodworks reports Q1 FY27 financial results.* The company posted revenue of **₹523 crore** and net profit of **₹33.2 crore**, showing **12% YoY growth** in same-store sales. Margins improved due to operational efficiencies and supply chain optimization. 📊 *STOCKS:* $JUBLFOOD | 🏢 *SECTOR:* FMCG | #HIGHIMPACT #Earnings
Jubilant Foodworks reports Q1 FY27 financial results
*Jubilant Foodworks reports Q1 FY27 financial results.* The company has announced its financial performance for the quarter ended June 30, 2026. Results include key metrics such as revenue, profit, and operational updates. **Figures** will impact investor sentiment and near-term price action. 📊 *STOCKS:* $JUBLFOOD | 🏢 *SECTOR:* CapitalMarkets | #HIGHIMPACT #Earnings
Jubilant Ingrevia to release Q2 and H1 FY27 results
*Jubilant Ingrevia to release Q2 and H1 FY27 results.* The company will present its financial and operational performance for the quarter and half year ended September 30, 2026. Traders will focus on revenue growth, margin trends, and guidance. Key metrics include **Q2 revenue**, **EBITDA margin**, and **net profit**. 📊 *STOCKS:* JUBLINGREA | 🏢 *SECTOR:* Chemicals | #MEDIUMIMPACT #Earnings
Jubilant Pharmova receives GST show cause notice
*Jubilant Pharmova receives GST show cause notice.* The company disclosed receipt of a show cause notice related to GST dues. While the exact amount is not specified, such notices may lead to financial liability or legal proceedings. This could impact near-term sentiment and stock performance. 📊 *STOCKS:* JUBLPHARMA | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #GST
Jubilant Ingrevia shares unchanged after investor presentation.
*Jubilant Ingrevia shares showed no significant movement following its investor presentation.* The presentation detailed the company’s business operations and strategic outlook without any **major financial announcements** or surprises. Traders await upcoming quarterly results for clearer direction. 📊 *STOCKS:* $JUBLING | 🏢 *SECTOR:* CapitalMarkets | #LOWIMPACT #CorporateUpdate
Financials
Quarterly Results
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹2.3K Cr 7.9% | ₹2.1K Cr 7.9% | ₹2.0K Cr 3.4% | ₹1.9K Cr 1.5% | ₹1.9K Cr 5.9% | ₹1.8K Cr 4.0% | ₹1.8K Cr 1.2% | ₹1.7K Cr |
| Op. Profit | ₹339 Cr 17.3% | ₹289 Cr 15.2% | ₹341 Cr 17.6% | ₹290 Cr 15.9% | ₹345 Cr 20.2% | ₹287 Cr 0.7% | ₹289 Cr 14.7% | ₹252 Cr |
| OPM | 15.0% 7.1% | 14.0% 17.6% | 17.0% 13.3% | 15.0% 16.7% | 18.0% 12.5% | 16.0% 5.9% | 17.0% 13.3% | 15.0% |
| Net Profit | ₹119 Cr 112.5% | ₹56 Cr 53.3% | ₹120 Cr 17.6% | ₹102 Cr 32.5% | ₹151 Cr 49.5% | ₹101 Cr 1.0% | ₹102 Cr 78.8% | ₹482 Cr |
| EPS (₹) | 7.5 113.7% | 3.51 53.5% | 7.55 16.9% | 6.46 33.0% | 9.64 52.3% | 6.33 1.9% | 6.45 78.7% | 30.26 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹8.3K Cr 14.5% | ₹7.2K Cr 7.9% | ₹6.7K Cr 6.7% | ₹6.3K Cr 2.5% | ₹6.1K Cr 0.5% | ₹6.1K Cr 2.1% | ₹6.0K Cr 34.4% | ₹9.1K Cr 21.2% | ₹7.5K Cr 28.3% | ₹5.9K Cr |
| Expenses | ₹7.0K Cr 15.8% | ₹6.1K Cr 4.5% | ₹5.8K Cr 5.4% | ₹5.5K Cr 10.5% | ₹5.0K Cr 6.1% | ₹4.7K Cr 6.0% | ₹4.4K Cr 39.9% | ₹7.4K Cr 22.9% | ₹6.0K Cr 32.9% | ₹4.5K Cr |
| Op. Profit | ₹1.3K Cr 7.4% | ₹1.2K Cr 30.2% | ₹901 Cr 15.7% | ₹779 Cr 32.3% | ₹1.1K Cr 18.0% | ₹1.4K Cr 9.4% | ₹1.5K Cr 11.2% | ₹1.7K Cr 14.6% | ₹1.5K Cr 12.6% | ₹1.4K Cr |
| OPM | 15.0% 6.3% | 16.0% 23.1% | 13.0% 8.3% | 12.0% 36.8% | 19.0% 17.4% | 23.0% 11.5% | 26.0% 36.8% | 19.0% 5.0% | 20.0% 13.0% | 23.0% |
| Other Income | ₹7 Cr 98.3% | ₹416 Cr 647.4% | ₹-76 Cr 744.4% | ₹-9 Cr 212.5% | ₹8 Cr 97.0% | ₹263 Cr 16.9% | ₹225 Cr 190.4% | ₹-249 Cr 791.7% | ₹36 Cr 89.5% | ₹19 Cr |
| Interest | ₹212 Cr 11.7% | ₹240 Cr 11.8% | ₹272 Cr 44.7% | ₹188 Cr 29.7% | ₹145 Cr 21.2% | ₹184 Cr 8.0% | ₹200 Cr 9.1% | ₹220 Cr 22.5% | ₹284 Cr 16.7% | ₹341 Cr |
| Depreciation | ₹440 Cr 19.2% | ₹369 Cr 3.4% | ₹382 Cr 31.0% | ₹554 Cr 45.0% | ₹382 Cr 9.5% | ₹349 Cr 2.6% | ₹340 Cr 8.4% | ₹371 Cr 10.6% | ₹415 Cr 42.6% | ₹291 Cr |
| PBT | ₹614 Cr 37.4% | ₹981 Cr 477.1% | ₹170 Cr 507.1% | ₹28 Cr 95.6% | ₹630 Cr 44.4% | ₹1.1K Cr 8.1% | ₹1.2K Cr 36.4% | ₹904 Cr 5.2% | ₹859 Cr 16.4% | ₹738 Cr |
| Tax % | 35.0% 133.3% | 15.0% 73.7% | 57.0% 82.9% | 333.0% 879.4% | 34.0% 30.8% | 26.0% 3.7% | 27.0% 25.0% | 36.0% 38.5% | 26.0% 18.2% | 22.0% |
| Net Profit | ₹398 Cr 52.4% | ₹836 Cr 1045.2% | ₹73 Cr 212.3% | ₹-65 Cr 115.7% | ₹413 Cr 50.6% | ₹836 Cr 6.9% | ₹898 Cr 55.6% | ₹577 Cr 9.0% | ₹634 Cr 10.3% | ₹575 Cr |
| EPS (₹) | 25.02 52.5% | 52.69 988.6% | 4.84 226.4% | -3.83 114.7% | 25.98 50.5% | 52.47 7.0% | 56.39 56.4% | 36.06 10.6% | 40.35 11.6% | 36.14 |
| Div Payout | 20.0% 122.2% | 9.0% 91.2% | 102.0% 178.5% | -130.0% 784.2% | 19.0% 90.0% | 10.0% 11.1% | 9.0% 25.0% | 12.0% 71.4% | 7.0% 12.5% | 8.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr 0.0% | ₹16 Cr |
| Reserves | ₹7.1K Cr 13.4% | ₹6.2K Cr 15.2% | ₹5.4K Cr 0.7% | ₹5.4K Cr 1.5% | ₹5.3K Cr 12.2% | ₹4.7K Cr 15.4% | ₹5.6K Cr 16.6% | ₹4.8K Cr 17.7% | ₹4.1K Cr 19.0% | ₹3.4K Cr |
| Borrowings | ₹3.6K Cr 32.4% | ₹2.7K Cr 25.5% | ₹3.7K Cr 0.4% | ₹3.7K Cr 15.2% | ₹3.2K Cr 12.8% | ₹2.8K Cr 41.1% | ₹4.8K Cr 0.7% | ₹4.8K Cr 39.5% | ₹3.5K Cr 14.2% | ₹4.0K Cr |
| Other Liabilities | ₹4.6K Cr 26.8% | ₹3.6K Cr 60.6% | ₹2.2K Cr 20.9% | ₹1.9K Cr 40.5% | ₹1.3K Cr 10.7% | ₹1.2K Cr 37.2% | ₹1.9K Cr 13.7% | ₹1.7K Cr 12.2% | ₹1.9K Cr 34.2% | ₹1.4K Cr |
| Total Liabilities | ₹15.3K Cr 21.4% | ₹12.6K Cr 11.0% | ₹11.3K Cr 3.7% | ₹10.9K Cr 11.2% | ₹9.8K Cr 12.2% | ₹8.8K Cr 28.8% | ₹12.3K Cr 8.8% | ₹11.3K Cr 19.7% | ₹9.5K Cr 6.3% | ₹8.9K Cr |
Assets | ||||||||||
| Fixed Assets | ₹7.0K Cr 34.6% | ₹5.2K Cr 1.7% | ₹5.1K Cr 1.8% | ₹5.2K Cr 6.4% | ₹4.9K Cr 5.7% | ₹4.6K Cr 27.3% | ₹6.3K Cr 12.3% | ₹5.6K Cr 4.6% | ₹5.4K Cr 5.8% | ₹5.1K Cr |
| CWIP | ₹4.0K Cr 11.3% | ₹3.6K Cr 72.6% | ₹2.1K Cr 34.6% | ₹1.6K Cr 43.3% | ₹1.1K Cr 21.5% | ₹897 Cr 16.8% | ₹768 Cr 14.8% | ₹901 Cr 34.3% | ₹671 Cr 1.9% | ₹684 Cr |
| Investments | ₹61 Cr 38.6% | ₹44 Cr 4.8% | ₹42 Cr 83.6% | ₹256 Cr 7.1% | ₹239 Cr 0.8% | ₹241 Cr 249.3% | ₹69 Cr 40.0% | ₹115 Cr 7.3% | ₹124 Cr 20.4% | ₹103 Cr |
| Other Assets | ₹4.2K Cr 12.6% | ₹3.7K Cr 8.9% | ₹4.1K Cr 4.4% | ₹3.9K Cr 8.2% | ₹3.6K Cr 20.4% | ₹3.0K Cr 41.2% | ₹5.1K Cr 10.3% | ₹4.7K Cr 42.7% | ₹3.3K Cr 8.5% | ₹3.0K Cr |
| Total Assets | ₹15.3K Cr 21.4% | ₹12.6K Cr 11.0% | ₹11.3K Cr 3.7% | ₹10.9K Cr 11.2% | ₹9.8K Cr 12.2% | ₹8.8K Cr 28.8% | ₹12.3K Cr 8.8% | ₹11.3K Cr 19.7% | ₹9.5K Cr 6.3% | ₹8.9K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹1.2K Cr 14.5% | ₹1.1K Cr 10.4% | ₹971 Cr 46.9% | ₹661 Cr 21.1% | ₹838 Cr 53.0% | ₹1.8K Cr 15.6% | ₹1.5K Cr 37.5% | ₹1.1K Cr 13.9% | ₹1.3K Cr 2.8% | ₹1.3K Cr |
| Investing CF | ₹-1.1K Cr 323.2% | ₹512 Cr 185.9% | ₹-596 Cr 25.7% | ₹-474 Cr 46.7% | ₹-323 Cr 55.6% | ₹-727 Cr 172.3% | ₹-267 Cr 73.8% | ₹-1.0K Cr 65.8% | ₹-614 Cr 32.0% | ₹-465 Cr |
| Financing CF | ₹95 Cr 106.5% | ₹-1.5K Cr 236.3% | ₹-432 Cr 175.2% | ₹-157 Cr 375.8% | ₹-33 Cr 98.1% | ₹-1.7K Cr 62.8% | ₹-1.1K Cr 259.8% | ₹657 Cr 172.9% | ₹-901 Cr 31.3% | ₹-686 Cr |
| Net Cash Flow | ₹179 Cr 35.6% | ₹132 Cr 327.6% | ₹-58 Cr 293.3% | ₹30 Cr 93.8% | ₹482 Cr 173.9% | ₹-652 Cr 389.8% | ₹225 Cr 70.4% | ₹761 Cr 459.0% | ₹-212 Cr 281.2% | ₹117 Cr |
| Free Cash Flow | ₹-120 Cr 215.8% | ₹-38 Cr 145.8% | ₹83 Cr 161.5% | ₹-135 Cr 156.0% | ₹241 Cr 81.0% | ₹1.3K Cr 30.3% | ₹975 Cr 106.1% | ₹473 Cr 42.2% | ₹819 Cr 1.6% | ₹806 Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 47d 4.4% | 45d 10.0% | 50d 10.7% | 56d 1.8% | 55d 12.2% | 49d 38.0% | 79d 54.9% | 51d 7.3% | 55d 12.7% | 63d |
| Inventory Days | 170d 4.5% | 178d 19.1% | 220d 17.9% | 268d 13.0% | 308d 14.9% | 268d 42.1% | 463d 215.0% | 147d 16.9% | 177d 20.6% | 223d |
| Days Payable | 170d 7.6% | 158d 8.2% | 146d 8.8% | 160d 15.1% | 139d 12.1% | 124d 54.6% | 273d 157.5% | 106d 26.9% | 145d 5.8% | 137d |
| Cash Conv. Cycle | 47d 27.7% | 65d 47.6% | 124d 24.8% | 165d 26.3% | 224d 15.5% | 194d 27.6% | 268d 191.3% | 92d 5.7% | 87d 41.6% | 149d |
| Working Capital Days | 13d 18.8% | 16d 71.4% | 56d 1.8% | 57d 1.8% | 56d 24.3% | 74d 19.4% | 62d 37.8% | 45d 0.0% | 45d 10.0% | 50d |
| ROCE | 9.0% 10.0% | 10.0% 42.9% | 7.0% 133.3% | 3.0% 70.0% | 10.0% 16.7% | 12.0% 20.0% | 15.0% 6.3% | 16.0% 6.7% | 15.0% 0.0% | 15.0% |
Source: Screener.in · Lower days = better efficiency
About Jubilant Pharmova Limited
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs.[1]
HealthcarePharmaceuticals & Biotechnology